Literature DB >> 25652448

SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models.

Davi A G Mázala1, Stephen J P Pratt2, Dapeng Chen1, Jeffery D Molkentin3, Richard M Lovering2, Eva R Chin4.   

Abstract

Duchenne muscular dystrophy (DMD) is characterized by progressive muscle wasting secondary to repeated muscle damage and inadequate repair. Elevations in intracellular free Ca²⁺ have been implicated in disease progression, and sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 1 (SERCA1) overexpression has been shown to ameliorate the dystrophic phenotype in mdx mice. The purpose of this study was to assess the effects of SERCA1 overexpression in the more severe mdx/Utr(-/-) mouse model of DMD. Mice overexpressing SERCA1 were crossed with mdx/Utr ± mice to generate mdx/Utr(-/-)/+SERCA1 mice and compared with wild-type (WT), WT/+SERCA1, mdx/+SERCA1, and genotype controls. Mice were assessed at ∼12 wk of age for changes in Ca²⁺ handling, muscle mass, quadriceps torque, markers of muscle damage, and response to repeated eccentric contractions. SERCA1-overexpressing mice had a two- to threefold increase in maximal sarcoplasmic reticulum Ca²⁺-ATPase activity compared with WT which was associated with normalization in body mass for both mdx/+SERCA1 and mdx/Utr(-/-)/+SERCA1. Torque deficit in the quadriceps after eccentric injury was 2.7-fold greater in mdx/Utr(-/-) vs. WT mice, but only 1.5-fold greater in mdx/Utr(-/-)/+SERCA1 vs. WT mice, an attenuation of 44%. Markers of muscle damage (% centrally nucleated fibers, necrotic area, and serum creatine kinase levels) were higher in both mdx and mdx/Utr(-/-) vs. WT, and all were attenuated by overexpression of SERCA1. These data indicate that SERCA1 overexpression ameliorates functional impairments and cellular markers of damage in a more severe mouse model of DMD. These findings support targeting intracellular Ca²⁺ control as a therapeutic approach for DMD.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  Duchenne muscular dystrophy; SERCA1; calcium; injury; mdx; mdx/Utr−/−

Mesh:

Substances:

Year:  2015        PMID: 25652448      PMCID: PMC4420794          DOI: 10.1152/ajpcell.00341.2014

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  80 in total

Review 1.  Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.

Authors:  Urs T Ruegg; Valérie Nicolas-Métral; Corinne Challet; Katy Bernard-Hélary; Olivier M Dorchies; Stéphanie Wagner; Timo M Buetler
Journal:  Neuromuscul Disord       Date:  2002-10       Impact factor: 4.296

2.  Role of the calcium-calpain pathway in cytoskeletal damage after eccentric contractions.

Authors:  Bao-Ting Zhang; Simon S Yeung; David G Allen; Ling Qin; Ella W Yeung
Journal:  J Appl Physiol (1985)       Date:  2008-05-22

3.  TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice.

Authors:  Jarrod A Call; James M Ervasti; Dawn A Lowe
Journal:  J Appl Physiol (1985)       Date:  2011-05-12

4.  Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.

Authors:  J A Rafael; J M Tinsley; A C Potter; A E Deconinck; K E Davies
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

5.  Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress.

Authors:  W J Leijendekker; A C Passaquin; L Metzinger; U T Rüegg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

6.  The role of proteases in excitation-contraction coupling failure in muscular dystrophy.

Authors:  Davi A G Mázala; Robert W Grange; Eva R Chin
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-08       Impact factor: 4.249

Review 7.  Calpains and muscular dystrophies.

Authors:  J G Tidball; M J Spencer
Journal:  Int J Biochem Cell Biol       Date:  2000-01       Impact factor: 5.085

8.  A stepwise procedure to test contractility and susceptibility to injury for the rodent quadriceps muscle.

Authors:  Stephen J P Pratt; Richard M Lovering
Journal:  J Biol Methods       Date:  2014

9.  Twitch and tetanus in mdx mouse muscle.

Authors:  J G Quinlan; S R Johnson; M K McKee; S P Lyden
Journal:  Muscle Nerve       Date:  1992-07       Impact factor: 3.217

10.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin.

Authors:  J M Ervasti; K P Campbell
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  25 in total

1.  Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Yongping Yue; William Lostal; Lakmini P Wasala; Nandita Niranjan; Roger J Hajjar; Gopal J Babu; Dongsheng Duan
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

2.  Variable cytoplasmic actin expression impacts the sensitivity of different dystrophin-deficient mdx skeletal muscles to eccentric contraction.

Authors:  Angus Lindsay; William M Southern; Preston M McCourt; Alexie A Larson; James S Hodges; Dawn A Lowe; James M Ervasti
Journal:  FEBS J       Date:  2019-04-11       Impact factor: 5.542

3.  Sarcolipin deletion in mdx mice impairs calcineurin signalling and worsens dystrophic pathology.

Authors:  Val A Fajardo; Paige J Chambers; Emma S Juracic; Bradley A Rietze; Daniel Gamu; Catherine Bellissimo; Frenk Kwon; Joe Quadrilatero; A Russell Tupling
Journal:  Hum Mol Genet       Date:  2018-12-01       Impact factor: 6.150

4.  Measurement of Skeletal Muscle Fiber Contractility with High-Speed Traction Microscopy.

Authors:  Martin Rausch; David Böhringer; Martin Steinmann; Dirk W Schubert; Stefan Schrüfer; Christoph Mark; Ben Fabry
Journal:  Biophys J       Date:  2019-12-24       Impact factor: 4.033

5.  Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca2+ cycling in vivo.

Authors:  Michelle L Law; Kurt W Prins; Megan E Olander; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-17       Impact factor: 4.733

Review 6.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela E Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 7.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-12-01

8.  Mechanisms of weakness in Mdx muscle following in vivo eccentric contractions.

Authors:  Cory W Baumann; Christopher P Ingalls; Dawn A Lowe
Journal:  J Muscle Res Cell Motil       Date:  2022-04-20       Impact factor: 3.352

9.  Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice.

Authors:  Ken'ichiro Nogami; Yusuke Maruyama; Fusako Sakai-Takemura; Norio Motohashi; Ahmed Elhussieny; Michihiro Imamura; Satoshi Miyashita; Megumu Ogawa; Satoru Noguchi; Yuki Tamura; Jun-Ichi Kira; Yoshitsugu Aoki; Shin'ichi Takeda; Yuko Miyagoe-Suzuki
Journal:  Hum Mol Genet       Date:  2021-05-31       Impact factor: 6.150

10.  Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype.

Authors:  Val A Fajardo; Eric Bombardier; Elliott McMillan; Khanh Tran; Brennan J Wadsworth; Daniel Gamu; Andrew Hopf; Chris Vigna; Ian C Smith; Catherine Bellissimo; Robin N Michel; Mark A Tarnopolsky; Joe Quadrilatero; A Russell Tupling
Journal:  Dis Model Mech       Date:  2015-05-28       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.